Researchers have developed a new risk model to predict the survival of patients with esophageal squamous cell carcinoma (ESCC) based on four genes (ANXA10, ERICH5, HRG, and AMN) associated with purinergic signaling pathways and sensitivity to chemoradiotherapy. The study analyzed patient data from the TCGA-ESCC database and identified differences in the expression of these genes between tumor and healthy tissue, with ANXA10, AMN and ERICH5 downregulated and HRG upregulated in tumors. High-risk patients according to this model showed increased infiltration of certain immune cells and better response to specific drugs such as VX.702 and BMS.754807. The results were experimentally verified using the RT-qPCR method. The created risk model could help in predicting the survival of patients and contribute to a personalized approach in the diagnosis and treatment of ESCC.